Imel EA - Search Results

1

Pharmacological management of X-linked hypophosphataemia.

Imel EA, White KE. Imel EA, et al. Br J Clin Pharmacol. 2019 Jun;85(6):1188-1198. doi: 10.1111/bcp.13763. Epub 2018 Oct 29. Br J Clin Pharmacol. 2019. PMID: 30207609 Free PMC article. Review.

2

A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.

Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, Goetz R, Mohammadi M, White KE, Econs MJ. Ichikawa S, et al. Among authors: imel ea. J Clin Invest. 2007 Sep;117(9):2684-91. doi: 10.1172/JCI31330. J Clin Invest. 2007. PMID: 17710231 Free PMC article.

3

A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.

Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, Goetz R, Mohammadi M, White KE, Econs MJ. Ichikawa S, et al. Among authors: imel ea. J Musculoskelet Neuronal Interact. 2007 Oct-Dec;7(4):318-9. J Musculoskelet Neuronal Interact. 2007. PMID: 18094491 Free article. No abstract available.

4

Mutational survey of the PHEX gene in patients with X-linked hypophosphatemic rickets.

Ichikawa S, Traxler EA, Estwick SA, Curry LR, Johnson ML, Sorenson AH, Imel EA, Econs MJ. Ichikawa S, et al. Among authors: imel ea. Bone. 2008 Oct;43(4):663-6. doi: 10.1016/j.bone.2008.06.002. Epub 2008 Jun 18. Bone. 2008. PMID: 18625346 Free PMC article.

5

Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations.

Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ. Imel EA, et al. J Clin Endocrinol Metab. 2010 Apr;95(4):1846-50. doi: 10.1210/jc.2009-1671. Epub 2010 Feb 15. J Clin Endocrinol Metab. 2010. PMID: 20157195 Free PMC article. Clinical Trial.

6

Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho).

Farrow EG, Imel EA, White KE. Farrow EG, et al. Among authors: imel ea. Best Pract Res Clin Rheumatol. 2011 Oct;25(5):735-47. doi: 10.1016/j.berh.2011.10.020. Best Pract Res Clin Rheumatol. 2011. PMID: 22142751 Free PMC article. Review.

7

The changing face of hypophosphatemic disorders in the FGF-23 era.

Lee JY, Imel EA. Lee JY, et al. Among authors: imel ea. Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2(0 2):367-79. Pediatr Endocrinol Rev. 2013. PMID: 23858620 Free PMC article. Review.

8

Iron and fibroblast growth factor 23 in X-linked hypophosphatemia.

Imel EA, Gray AK, Padgett LR, Econs MJ. Imel EA, et al. Bone. 2014 Mar;60:87-92. doi: 10.1016/j.bone.2013.12.001. Epub 2013 Dec 8. Bone. 2014. PMID: 24325979 Free PMC article.

9

Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia.

Zhang X, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey J, Glorieux FH, Portale AA, Insogna K, Carpenter TO, Peacock M. Zhang X, et al. Among authors: imel ea. J Clin Pharmacol. 2016 Feb;56(2):176-85. doi: 10.1002/jcph.570. Epub 2015 Aug 11. J Clin Pharmacol. 2016. PMID: 26073451 Free PMC article. Clinical Trial.

10

Population pharmacokinetic and pharmacodynamic analyses from a 4-month intradose escalation and its subsequent 12-month dose titration studies for a human monoclonal anti-FGF23 antibody (KRN23) in adults with X-linked hypophosphatemia.

Zhang X, Peyret T, Gosselin NH, Marier JF, Imel EA, Carpenter TO. Zhang X, et al. Among authors: imel ea. J Clin Pharmacol. 2016 Apr;56(4):429-38. doi: 10.1002/jcph.611. Epub 2015 Oct 26. J Clin Pharmacol. 2016. PMID: 26247790

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

89 results

Search Page